Australia - inglés - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate - fast, temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe easier.

Estados Unidos - inglés - NLM (National Library of Medicine)

cypress pharmaceutical, inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - hydrocodone bitartrate, pseudoephedrine hydrochloride, and chlorpheniramine maleate is indicated for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. important limitations of use - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4) ]. - contraindicated in pediatric patients less than 6 years of age [see contraindications (4) ]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve hydrocodone bitartrate, pseudoephedrine hydrochloride, and chlorpheniramine maleate for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. hydrocodone bitartrate, pseudoephedrine hydrochloride, and chlorpheniramine maleate is contraindicated for: -

Malta - inglés - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - triprolidine hydrochloride, pseudoephedrine hydrochloride - oral solution - triprolidine hydrochloride 1.25 mg pseudoephedrine hydrochloride 30 mg - nasal preparations

Malta - inglés - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - pseudoephedrine hydrochloride, triprolidine hydrochloride - oral solution - pseudoephedrine hydrochloride 30 mg triprolidine hydrochloride 1.25 mg - nasal preparations

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - paracetamol; pseudoephedrine hydrochloride - tablet - 500/30 milligram(s) - anilides; paracetamol; sympathomimetics; pseudoephedrine

Estados Unidos - inglés - NLM (National Library of Medicine)

sti pharma llc - triprolidine hydrochloride (unii: yan7r5l890) (triprolidine - unii:2l8t9s52qm), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - triprolidine hydrochloride 1.25 mg in 5 ml - triacin-c is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. triacin-c is contraindicated under the following conditions: codeine sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. this drug should not be used in newborn or premature infants. antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (mao) inhibitor therapy (see precautions - drug interactions ). like other medications containing a narcotic, triacin-c is controlled by the drug enforcemen

Estados Unidos - inglés - NLM (National Library of Medicine)

dispensing solutions, inc. - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - antihistamine nasal decongestant

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - antihistamine nasal decongestant

Estados Unidos - inglés - NLM (National Library of Medicine)

proficient rx lp - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - antihistamine nasal decongestant

Estados Unidos - inglés - NLM (National Library of Medicine)

ucb, inc. - acrivastine (unii: a20f9xai7w) (acrivastine - unii:a20f9xai7w), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - capsule - 8 mg - semprex-d capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. semprex-d capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see clinical pharmacology). the efficacy of semprex-d capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. semprex-d capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. semprex-d capsules are contraindicated in patients with a known sensitivity to acrivastine, other alkylamine antihistamines (e.g., triprolidine), pseudoephedrine, other sympathomimetic amines (e.g., phenylpropanolamine), or to any other components of the formulation. semprex-d capsules are contraindicated in patients with severe hypertension or severe coronary arter